Q4 and FY 2025 results Continuously delivering solid profitable growth February 4, 2026 Forward looking and intended use statements Safe Harbor Statement: Certain statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as "believe", "hope", "pl ...

Company Further Examining the Pursuit of the World's First Oral Liraglutide Product KELOWNA, BC / ACCESS Newswire / February 5, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce final results from Human Pilot Study #5 (GLP-1-H25-5) (the "Study"), which compared oral DehydraTECH-liraglutide ("DHT-LIR") capsules to injected Saxenda® branded liraglutide ("SAX-LIR"). "We are extremely pleased with the results of Huma ...

NEW YORK, Feb. 5, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Vistagen Therapeutics, Inc. (NASDAQ: VTGN). Shareholders who purchased shares of VTGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/vistagen-therapeutics-inc-loss-submission-form/?id=183358&from=4 CLASS PER ...

Core Insights - AIM ImmunoTech Inc. reported positive data from the ongoing Phase 2 clinical study of Ampligen combined with AstraZeneca's Imfinzi for treating metastatic pancreatic cancer, showing median survival of 19.7 months compared to 8.6 months with standard care [1][2] - The study aims to assess the clinical benefit rate, overall survival, progression-free survival, immune monitoring, and quality of life for patients [2][3] Group 1: Clinical Study Details - The DURIPANC study is an exploratory, open-label trial expected to enroll up to 25 subjects, with 18 patients already enrolled [3] - The study has shown promising results in progression-free survival and overall survival, with no significant toxicity reported, indicating a favorable safety profile [3][4] - The combination therapy appears to enhance the body's immune response, suggesting a coordinated activation of both innate and adaptive immune systems [5] Group 2: Market Potential and Intellectual Property - AIM holds a U.S. patent for Ampligen as an oncology treatment in combination with anti-PD-L1 therapies, extending protection until August 9, 2039 [7] - The company has received orphan drug designations in pancreatic cancer from both the U.S. and EU, providing market exclusivity post-commercial approval [7][8] - AIM believes that advancing Ampligen to Phase 3 clinical trials could present significant financial opportunities for the company and its shareholders [5][8]

BOSTON, Feb. 5, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers, in collaboration with Quantum Leap Healthcare Collaborative (Quantum Leap), today announced the submission to the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application amendment for a planned Phase 2a clinical trial with TransCode's lead therapeutic candid ...

SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in February 2026 and will also participate in one-on-one investor meetings at each of these conferences. Guggenheim Emerging Outlook: Biotech Summit 2026 (February 11-12, 2026) Lo ...

SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year 2025 before market open on Thursday, February 26, 2026. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio ...

Core Viewpoint - Crescent Biopharma, a clinical-stage biotechnology company, is focused on advancing innovative therapies for cancer patients and will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 [1] Company Overview - Crescent Biopharma aims to become a leading oncology company by developing the next generation of cancer therapies [3] - The company's clinical-stage pipeline includes a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates (ADCs) [3] - Crescent intends to leverage multiple modalities and established targets to advance transformative therapies for solid tumors, either as single agents or in combination regimens [3] Event Participation - Management is scheduled to participate in a fireside chat on February 12, 2026, at 11:30 a.m. ET [1] - A live webcast of the presentation will be available on the company's website, with a replay accessible for 90 days post-event [2]

RESEARCH TRIANGLE PARK, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2025 financial results on Thursday, February 26, 2026. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live we ...

SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026. The fireside chat session is scheduled for Thursday, February 12, in New York, ...